https://orcid.org/0000-0003-1881-4523
References
- Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95(7):848–860. doi:10.1002/ajh.25819
- Mayo Clinic. Mayo consensus on AL amyloidosis: diagnosis, treatment, and prognosis; 2020. Available from: https://www.msmart.org/. Accessed October 28, 2021.
- Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Hematology Am Soc Hematol Educ Program. 2020;2020(1):363–371. doi:10.1182/hematology.2020006913
- Sanchorawala V. Summary of the EHA-ISA Working Group guidelines for high-dose chemotherapy and stem cell transplantation for systemic AL amyloidosis. Hemasphere. 2022;6(2):e681. doi:10.1097/HS9.0000000000000681
- Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549. doi:10.1200/JCO.2011.37.7614
- Bayliss M, McCausland KL, Guthrie SD, White MK. The burden of amyloid light chain amyloidosis on health-related quality of life. Orphanet J Rare Dis. 2017;12(1):15. doi:10.1186/s13023-016-0564-2
- McCausland KL, Rizio AA, White MK, Bayliss MS, Quock TP. Associations between health-related quality of life and self-reported emergency room department visits and inpatient hospitalizations: insights from a secondary data analysis of patients with Light-Chain (AL) Amyloidosis. Pharmacoecon Open. 2019;3(3):367–375. doi:10.1007/s41669-019-0122-7
- Maruish ME. User’s Manual for the SF-36v2 Health Survey. 3rd ed. Lincoln, RI: QualityMetric Incorporated, LLC; 2011.
- White MK, Bayliss MS, Guthrie SD, Raymond KP, Rizio AA, McCausland KL. Content validation of the SF-36v2® health survey with AL amyloidosis patients. J Patient Rep Outcomes. 2017;1(1):13. doi:10.1186/s41687-017-0020-7
- White MK, McCausland KL, Sanchorawala V, Guthrie SD, Bayliss MS. Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Relat Outcome Meas. 2017;8:157–167. doi:10.2147/PROM.S146849
- Popkova T, Hajek R, Jelinek T. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits. Br J Haematol. 2020;189(2):228–238. doi:10.1111/bjh.16436
- Lin HM, Seldin D, Hui A-M, Berg D, Dietrich CN, Flood E. The patient’s perspective on the symptom and everyday life impact of AL amyloidosis. Amyloid. 2015;22(4):244–251. doi:10.3109/13506129.2015.1102131
- Seldin DC, Anderson JJ, Sanchorawala V, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004;104(6):1888–1893. doi:10.1182/blood-2004-01-0089
- Carter J-P, Foard D, Rannigan L, et al. A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. Amyloid. 2017;24(sup1):72–73. doi:10.1080/13506129.2017.1295944
- Cohen O, Rendas-Baum R, McCausland K, et al. Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light-chain amyloidosis. Br J Haematol. 2023;201(3):422–431. doi:10.1111/bjh.18645